Choreo LLC trimmed its holdings in shares of Sanofi (NASDAQ:SNY - Free Report) by 21.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 45,889 shares of the company's stock after selling 12,555 shares during the quarter. Choreo LLC's holdings in Sanofi were worth $2,545,000 at the end of the most recent reporting period.
Other hedge funds also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD boosted its stake in shares of Sanofi by 88.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 10,843,682 shares of the company's stock valued at $522,991,000 after purchasing an additional 5,091,304 shares in the last quarter. Point72 Asset Management L.P. lifted its position in Sanofi by 969.6% during the fourth quarter. Point72 Asset Management L.P. now owns 950,649 shares of the company's stock valued at $45,850,000 after acquiring an additional 861,770 shares during the last quarter. Regal Partners Ltd purchased a new stake in Sanofi during the fourth quarter valued at approximately $35,034,000. Vestal Point Capital LP lifted its position in Sanofi by 400.0% during the fourth quarter. Vestal Point Capital LP now owns 750,000 shares of the company's stock valued at $36,172,000 after acquiring an additional 600,000 shares during the last quarter. Finally, Northern Trust Corp lifted its position in Sanofi by 44.9% during the fourth quarter. Northern Trust Corp now owns 1,930,560 shares of the company's stock valued at $93,111,000 after acquiring an additional 597,959 shares during the last quarter. 14.04% of the stock is currently owned by institutional investors.
Sanofi Trading Up 0.5%
SNY stock traded up $0.24 during trading on Friday, reaching $50.37. 1,468,581 shares of the stock were exchanged, compared to its average volume of 2,528,303. The company has a current ratio of 1.37, a quick ratio of 0.69 and a debt-to-equity ratio of 0.16. The business has a 50 day moving average price of $49.57 and a 200-day moving average price of $52.10. Sanofi has a 1 year low of $45.80 and a 1 year high of $60.12. The firm has a market capitalization of $123.53 billion, a price-to-earnings ratio of 17.99, a P/E/G ratio of 1.14 and a beta of 0.48.
Sanofi (NASDAQ:SNY - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The company reported $0.94 EPS for the quarter, topping the consensus estimate of $0.90 by $0.04. Sanofi had a net margin of 14.56% and a return on equity of 17.15%. The firm had revenue of $10.41 billion for the quarter, compared to analyst estimates of $9.79 billion. During the same period in the prior year, the business posted $1.78 EPS. The business's revenue for the quarter was down 11.0% compared to the same quarter last year. On average, research analysts predict that Sanofi will post 4.36 earnings per share for the current year.
Analyst Ratings Changes
A number of equities research analysts recently commented on SNY shares. Morgan Stanley set a $56.00 target price on shares of Sanofi in a research report on Monday, June 2nd. Hsbc Global Res raised shares of Sanofi to a "strong-buy" rating in a report on Monday, April 28th. Guggenheim reiterated a "buy" rating on shares of Sanofi in a research note on Tuesday, June 3rd. Barclays reaffirmed an "overweight" rating on shares of Sanofi in a report on Wednesday, July 2nd. Finally, BNP Paribas started coverage on shares of Sanofi in a research report on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $61.50.
Check Out Our Latest Stock Report on Sanofi
Sanofi Company Profile
(
Free Report)
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Further Reading
Before you consider Sanofi, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.
While Sanofi currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
